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1. Introduction
  The patients of bronchogenic carcinoma (BCA) are 
debilitated and immunocompromised, and hence, are more 
prone to secondary pulmonary infections, both bacterial 
and fungal, due to cancerous involvement of the pulmonary 
tissue itself, and in particular, due to long term steroid 
and anticancer therapy. The early diagnosis of these 
secondary infections in such patients could be rewarding. 
Recently, we described frequent association between BCA 
and secondary aspergillosis especially with non-small 
cell lung cancer[1]. While performing bacterial cultures of 
bronchoalveolar lavages (BALs) of those patients we also 
noticed high occurrence of bacterial resistance to third and 
fourth generation cephalosporins especially in Escherichia 
coli (E. coli) and Klebsiella pneumoniae (K. pneumoniae) 
isolates.
  In recent years, CTX-M extended spectrum 毬-lactamases 
(ESBLs) have been increasingly reported in various 
clinical specimens[2-7]. However, we could not get any 
published study specifically looking for CTX-M and AmpC 
producing Enterobacteria in patients of BCA. It must again 
be emphasized here that early detection of such resistant 
bacteria could help improved outcome of the patients.
  Keeping in view the above facts, especially the paucity of 
literature, globally, we found worth looking frequency and 
occurrence of CTX-M and AmpC genogroups/genotypes, 
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their genetic environment; and to compare any relatedness 
or diversity in CTX-M carrying isolates obtained from BCA 
patients with those of isolates obtained from other clinical 
sources, including environmental isolates obtained from 
T.B. and Chest Diseases inpatients’ wards.
2. Material and methods
2.1. Study population
  The present study was conducted on patients of BCA 
attending the outpatient department or admitted in the 
wards of TB & Chest Diseases of J N Medical College & 
Hospital, AMU, Aligarh, India, From June 2003 to February 
2007. During this period, bronchoscopy was performed 
in 213 patients, of which 159 were suspected cases of 
bronchogenic carcinoma. A total of 95 confirmed patients of 
BCA (including 69 patients whose data on secondary fungal 
infections have previously been reported[1]), were included. 
A collection from 42 patients of BCA of the year 2001-2002 
was also included. Therefore, the study population for this 
study comprised of a total of 137 patients. Remaining 64 
suspected patients of BCA were excluded because of some 
other co-existing underlying immunosuppressive disorders 
or because the patients were taking antibacterial/ antifungal 
therapy. Thirty-four, age and sex matched volunteers, not 
having history suggestive of any lung disease in the recent 
past were included as healthy controls. Informed written 
consent was taken prior to bronchoscopy in all study and 
control groups and the investigations were performed after 
the approval by Institutional Ethical Committee.
2.2. Collection and processing of specimens
  BALs were collected for direct microscopy, bacterial and 
fungal culture, and BAL-PCR for fungal detection, and blood 
samples for serological tests detecting anti-Aspergillus 
antibodies. Bronchoscopy was performed by the expertise 
in T.B. Chest department. Two consecutive BAL specimens 
were collected in sterile containers with all aseptic 
precautions. Each BAL specimen was divided in three parts 
for direct microscopy, culture and PCR. 
2.3. Bacterial culture and identification
  BALs were subjected to bacterial culture on Blood agar 
(BA), Mac Conkey’s agar (MCA), and chocolate agar (CA). 
The BA and MCA plates were incubated aerobically, and CA 
plates in CO2 enriched environment, in candled jar, at 37 曟 
overnight, and the organisms were identified as per standard 
techniques[8]. Of the various bacterial isolates obtained from 
the culture of BAL specimens, only the isolates of E. coli 
and K. pneumoniae were selected for further phenotypic and 
molecular studies. 
2.4. Antibiotics susceptibility testing
  Disk susceptibility tests were performed and interpreted 
according to CLSI (formerly NCCLS) criteria[9] by using 
Mueller-Hinton agar (HiMedia Lab. Ltd., India). The 
antibiotics (HiMedia, India) and their concentrations 
(mg) are shown in Table 1. In vitro efficacy of ceftriaxone/
sulbactam (kindly provided by Ranbaxy Lab. Ltd., Gurgaon, 
India), which is a recently launched combination in India, 
was also evaluated. Since there are no published breakpoints 
for ceftriaxone/sulbactam combination, the susceptibility 
criteria used for this combination was as adopted in our 
earlier study[10].
2.5. Phenotypic ESBL detection by disk synergy tests
  ESBL detection was performed by disk synergy tests using 
co-amoxiclav[11] and piperacillin-tazobactam discs[10]. 
Phenotypic detection was also performed by combination 
disk method using cephalosporin disks alone, and in the 
presence of clavulanate.
2.6. Phenotypic detection of AmpC production
  Since there are no published CLSI criteria for phenotypic 
screening or confirmatory test for AmpC 毬-lactamases, 
a modified three-dimensional test (MTDT), as described 
previously[12], was used for the detection of AmpC 毬
-lactamase. The isolates selected for the MTDT were those 
which were screen positive i.e. those with cefoxitin zone 
diameter of < 18 mm and cefoxitin susceptible isolates 
(based on cefoxitin disk susceptibility) but were found to 
carry blaampC alleles.
Table 1
Antibiotics resistance rates in E. coli and K. pneumoniae isolates* 
obtained from BAL against first and second line antibiotics tested.
Antibiotics tested (毺g)
 Resistance [n (%)]
E. coli (n=21) K. pneumoniae (n=41)
Ampicillin (10) 95.2 (20) NT
Co-trimoxazole (1.2/23.8) 95.2 (20)        100.0 (41)
Tetracycline (30) 95.2 (20) 95.1 (39)
Ciprofloxacin (1) 90.5 (19) 73.2 (30)
Gentamicin (10) 66.7 (14) 63.4 (26)
Amikacin (30) 47.6 (10) 56.1 (23)
Tobramycin (10) 61.9 (13) 36.6 (15)
Cefotaxime (30) 90.5 (19) 92.7 (38)
Ceftazidime (30) 85.7 (18) 92.7 (38)
Cefpodoxime (10) 95.2 (20) 97.6 (40)
Cefpirome (30) 71.4 (15) 58.5 (24)
Cefepime (30) 71.4 (15) 58.5 (24)
Cefoxitin (30) 38.1 (8) 51.2 (21)
Aztreonam (30) 85.7 (18) 73.2 (30)
Trimethoprim (2.5) 85.7 (18) 85.4 (35)
Piperacillin (100)   100.0 (21)        100.0 (41)
Piperacillin/tazobactam (100/10)  90.5 (19) 97.6 (40)
Ticarcillin (75) 100.0 (21)        100.0 (41)
Ticarcillin/clavulanate (75/10)     100.0 (21)        100.0 (41)
Meropenem (10)     14.3 (3) 0.0 (0)
Ceftriaxone/sulbactam (30/15)     14.3 (3) 0.0 (0)
*The isolates were resistant to multiple antibiotics. 
NT = not tested.
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2.7. Multiplex PCRs for detection of blaCTX-M and blaampC
  Multiplex PCRs for the detection of blaCTX-M and blaampC 
were carried out using the primer sets and conditions 
as described by Woodford et al[13] and Perez-Perez & 
Hanson[14], respectively. After running the amplicons on 
2% agarose gel, the precise size of the band was determined 
using the “Quantity One” software provided with the Gel 
documentation system (BioRad U.S.A.). 
2.8. Nucleotide sequencing
  Representative isolates were randomly selected for DNA 
sequencing of the blaCTX-M open reading frame (ORF) and 
blaAmpC in order to find out the specific types. Whole ORF 
of blaCTX-M was amplified using primers ISEcp1 U1 (5’-AAA 
AAT GAT TGA AAG GTG GT-3’) and P2D (5’-CAG CGC TTT 
TGC CGT CTA AG-3’). For AmpC- sequencing, the same 
primer set (CIT Group) as used for multiplex PCR were used 
for sequencing. The PCR protocol used was that adopted in 
our previous studies[7]. 
2.9. Association of IS26 with blaCTX-M-15 
  All CTX-M-15-carrying isolates were screened using the 
PCR protocol described by Woodford et al[15]. A separate 
collection of bacteria from different specimens, collected 
for a parallel ongoing study, and detected to carry blaCTX-M, 
was also analyzed for the IS26 elements and compared with 
the isolates of this study in order to determine any similarity 
or dissimilarity in IS26 amplicon insertions in the two 
collections. 
 
2.10. RAPD-PCR typing
  All isolates found to carry blaCTX-M and blaampC were 
typed using the RAPD-PCR[16] to determine whether any 
predominant clone existed in this isolate collection. A 
separate collection of bacteria from different specimens, 
collected for a parallel ongoing study, and detected to carry 
blaCTX-M and blaampC, were also typed by RAPD and compared 
with the isolates of this study to determine any common 
circulating clone or diversity in clinical isolates obtained 
from different samples.  
3. Results
3.1. Patients’ demographic information and clinical 
presentations
  Of 137 patients, majority (56.9%) were in the age group of 
45-<60 years, followed by 60-<75 years (35.8%). The median 
age of the study population was 58 years and male to female 
ratio was 11.5:1. A total of 55 (40.1%) and 36(26.3%) patients 
underwent chemotherapy or took steroids 6 months prior to 
the study, respectively. 
  The most common presentation was with cough, which was 
noticed in 70% patients followed by expectoration and chest 
pain noticed in 52.6% and 50.4% patients, respectively. The 
detailed presenting features of the patients are shown in 
Figure 1.  
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Figure 1. Presenting features of the patients with bronchogenic 
carcinoma included in the present study.
* Most of the patients presented with multiple presenting features.
3.2. Bronchoscopic features and bronchogenic carcinoma 
types 
  The detailed bronchoscopic features of the patients, as 
revealed during bronchoscopy, are shown in Table 2. The 
most common finding noticed in the bronchoscopy was 
intraluminal growth observed in 79.6% cases. Most of the 
patients presented with mixed bronchoscopic findings. The 
bronchogenic carcinoma types, based on histopathological 
examinations, are shown in Figure 2.
Squamous cell       Adenocarcinoma       Small cell      Large cell      unidentified
25%
4% 3% 1%
67%
Figure 2. Bronchogenic carcinoma cell-types as identified by 
histopathological examination.
3.3. Bacterial isolates
  Out of 137 BAL specimens of BCA patients, 104-yielded 
bacterial growth on aerobic incubation, and a total of 143 
bacterial isolates (many samples showed mixed growth) 
were obtained. The details of the isolated bacteria are 
shown in Table 3. K. pneumoniae was the most frequent 
isolated organism noticed in 29.9% samples followed by 
Pseudomonas aeruginosa which was noticed in 26.3% BAL 
samples. E. coli was isolated from 15.3% samples. None 
of the BAL specimens from healthy volunteers provided 
growth of Enterobacteriaceae (data not shown). The bacterial 
population consisting of E. coli (n=21) and K. pneumoniae 
(n=41) was subjected for further testing.
3.4. Antibiotic susceptibility
  The detailed results of the antibiotic susceptibility 
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are presented in Table 1. The isolates of E. coli showed 
maximum susceptibility to ceftriaxone-sulbactam, a 
combination recently launched in India, and to meropenem 
in 85.7%, each, followed by cefoxitin (53.2%) and amikacin 
(46.8%). Concomitant high resistance to other antibiotics, 
including tetracycline (95.2%), co-trimoxazole (95.2%), 
ciprofloxacin (90.5%), aztreonam (85.7%), trimethoprim 
(85.7%), gentamicin (66.7%), was also noticed. 
  All the K. pneumoniae isolates were susceptible to 
ceftriaxone-sulbactam and imipenem. Similar to E. coli 
isolates, K. pneumoniae also showed concomitant high 
resistance to other antibiotics tested (Table 1).
3.5. Phenotypic ESBL and AmpC detection
  Comparative results of ESBL detection by these three tests 
are shown in Figure 3.
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Figure 3. Comparative analysis of the ESBL detection by three 
phenotypic tests used in the present study.
  None of the isolates, out of 62, could be detected as ESBL-
producers by applying amoxicillin-clavulanate at 30 mm, 
center to center (Figure 4 A-F). By applying amoxicillin-
clavulanate at a distance of 20 mm, we could only detect 
9.7% (6/62) isolates as ESBL-producers, of which 4 isolates 
were of E. coli and 2 were K. pneumoniae. Most of the 
isolates in the present study either did not or showed very 
small zones of inhibitions to cephalosporins.
Figure 4. Photograph of blaCTX-M-15 carrying isolates showing synergy 
between cephalosporins and piperacillin-tazobactam discs at 30 mm.
Non-detection of ESBL by co-amoxyclav even at 20 mm (A to D). 
Isolates not giving good synergy but still detected as ESBL-producers 
by ceftriaxone and cefotaxime and not by ceftazidime by using 
piperacillin-tazobactam disk (E & F).
  In the modified test, where piperacillin-tazobactam was 
used in place of co-amoxyclav disk, we could detect ESBLs 
in total of 90.3% (56/62) isolates, and of which, it could be 
detected in 85.7% (18/21) and 92.7% (38/41) isolates of E. coli 
and K. pneumoniae, respectively. Excellent synergy between 
piperacillin-tazobactam and cephalosporins, in all the 
isolates, was seen when the discs were placed 20 mm apart. 
When the discs were placed at 30 mm, still ESBL could 
be detected in all the isolates, most of the isolates giving 
excellent synergistic patterns as shown in Figure 4 A-D, 
however few of the isolates gave patterns as shown in Figure 
4 E & F. Comparative sensitivity of ceftriaxone, cefotaxime 
Table 2
Bronchoscopic features according to the cell-type of bronchogenic carcinoma (n=137).
Carcinoma-type No. of cases Vocal cord palsy Widened carina Intraluminal growth Compressed bronchi Congestion     Secretions
Squamous cell 91 26 26 86 24 41 56
Adenocarcinoma 34 5 - 14 19  6  8
Small cell 6 - -   5 - - -
Large cell 4 - -   4 - - -
Unidentified 2 - - - -  2  2
Total 137 31 26 109 43 49 66
* Many patients presented with multiple bronchoscopic findings. 
Table 3
Bacterial species isolated from 137 BAL fluids of BCA patients.
Bacteria isolated No. of isolates* Percentage
K. pneumoniae   41 29.9
Pseudomonas aeruginosa   36 26.3
E. coli   21 15.3
毬-hemolytic streptococci   15 10.9
Citrobacter spp.     9   6.6
Acinetobacter spp.     8   5.8
Staphylococcus aureus     6   4.4
Staphylococcus epidermidis     4   2.9
Diplococcus pneumoniae     3   2.2
Total 143 -
* Many specimens showed mixed bacterial growth.
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and ceftazidime in ESBL detection by using piperacillin-
tazobactam discs was found to be 90.3% (56/62), 88.7% (55/62), 
and 67.7% (42/62), respectively.
M 1   2  3  4   5   6  7  8   9 10 11 12 13 14 15 16 17 18  19 20 21 22 23 24 M
600
500
400
300
200
100
1500
900
600
500
400
300
200
100
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900
Figure 5. RAPD profile demonstrating diversity of the representative 
isolates carrying blaCTX-M and blaampC obtained from patients 
of bronchogenic carcinoma as well as from other clinical and 
environmental specimens. 
Lanes M show the molecular weight markers.
  Using the CDT method, ESBL production was detected 
in total of 82.3% (51/62) isolates. Of these, ESBLs could be 
detected in 76.2% (16/21) of E. coli and 85.4% (35/41) of K. 
pneumoniae isolates.
  A total of 19.4% (12/62) isolates were detected as AmpC-
producers by CDT, and of which 3 were E. coli and 9 were 
K. pneumoniae. Among the 29 cefoxitin-resistant isolates 
studied by modified three-dimensional test, 12 (3 E. coli 
and 9 K. pneumoniae) were detected as AmpC-producers, 
and 3 isolates (All K. pneumoniae) were inferred as AmpC-
intermediate. Simultaneous production of ESBLs and AmpC 
enzymes could be inferred in 14.5% (9/62) isolates by the 
phenotypic method described above.
3.6. Detection and characterization of blaCTX-M and blaAmpC 
alleles based on multiplex-PCR and sequencing
  blaCTX-M could be detected in 77.4% (48/62) isolates using 
the multiplex PCR. Noting the detection of blaCTX-M alleles in 
E. coli and K. pneumoniae, we found their presence in 81% 
(17/21) and 75.6% (31/41) isolates, respectively. Based on the 
PCR-amplicon size, all belonged to CTX-M phylogenetic 
Group 1. Of the 62 isolates, blaampC of CIT-family were 
detected in 27.4% (17/62) isolates. Of these blaampC-carrying 
isolates, 23.8% (5/21) were E. coli and 29.3% (12/41) were K. 
pneumoniae. The PCR assay detected blaampC in 15/29 (51.7%) 
of cefoxitin-resistant isolates. Two isolates found to carry 
blaampC were categorized as being susceptible to cefoxitin 
using the zone breakpoint of <18 mm to infer resistance.
3.7. Co-carriage of blaampC and blaCTX-M-15
  Of the 62 isolates studied, 13 (21%) were simultaneously 
harboring blaampC and blaCTX-M-15. The frequency of 
simultaneous occurrence in the respective species was 
noticed in 19% (4/21) and 22% (9/41) of E. coli and K. 
pneumoniae respectively.
3.8. Sequencing of representative isolates
  Further confirmation by sequencing in representative 
isolates confirmed the presence of blaCTX-M-15 (GenBank 
Accession numbers EF 371799 and EF 371800) and blaCMY-6 
(GenBank Accession Nos. EF 103125 and EF 103126).
3.9. Detection of IS26 element
  IS26 was detected in 20 of 48 (41.7%) isolates carrying 
blaCTX-M-15 (9 E.coli, 11 K. pneumoniae). Amplicons of ~650 
bp, ~750 bp, ~850 bp,  ~950 bp, ~1 100 bp, and >1 400 bp 
were obtained, the most common being ~850 bp (Table 5). 
Random analysis of the bacterial isolates, obtained from 
other clinical samples, for a parallel ongoing study also 
showed this diverse picture of varying IS26 fragments and 
even multiple banding patterns.
3.10. RAPD analysis
  RAPD-typing revealed the presence of diverse bacterial 
population and no predominant clone was identified in our 
Indian bacterial collection (Figure 5). 
3.11. Brief mycological data (detailed data not presented)
  BAL culture of 42 (30.7%) patients showed growth of 
Aspergillus species and 19 of these 42 patients revealed 
fungal elements in direct microscopic examination of BAL. 
Of these 42 culture-positive cases, 18 were categorized as 
cases of definite-IPA and 24 of probable-IPA as described 
in our earlier study[1]. Of the Aspergillus spp. isolated, 
Aspergillus fumigatus was the predominant species isolated 
from 26 (61.9%) cases followed by Aspergillus flavus in 38.1% 
(16/42) patients. On analysis of the isolation of Aspergillus 
spp. in various forms of IPA, it was noticed that Aspergillus 
fumigatus was isolated from 12 and 14 cases of definite- 
and probable-IPA, respectively, whereas, Aspergillus flavus 
was isolated from 6 and 10 cases of definite- and probable-
IPA, respectively. No Aspergilli was isolated from cases of 
possible and non-IPA, and none among the healthy controls 
showed growth of Aspergilli in the culture. On serological 
testing, the anti-Aspergillus antibodies could be detected 
in 48 (35%) patients, each, by DID and DBA. However, the 
Table 4
Distribution and patterns of IS26 insertion in CTX-M-15-producing 
isolates.
Fragment size
Detected in Total
E. coli K. pneumoniae
   ~650 bp 1   2   3
   ~750 bp 1   1   2
   ~850 bp 5   4   9
   ~950 bp 1   1   2
~1 100 bp 1   1   2
>1 400 bp 0   2   2
Total 9 11 20
* Most of the patients presented with multiple presenting features
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antibodies could be detected in 54 (39.4%) patients by ELISA. 
None among the healthy volunteers showed anti-Aspergillus 
antibodies in any of the serological test. Aspergillus-DNA 
could be detected in 51.8% (71/137) samples by PCR. The 
Aspergillus-DNA was detected in all the patients categorized 
as cases of definite-IPA and probable-IPA, however, it 
could be detected in 69.7% (23/33) and 9.7% (6/62) cases of 
possible- and non-IPA, respectively. Based on the present 
study, a strong association between a positive PCR test and 
all forms of aspergillosis (P<0.05) was noticed, with the 
strongest association correlation found with definite- and 
probable-IPA (P< 0.001).
  When the data was compared statistically with entire 
dataset, the sentitivity of PCR and serological tests was 
noted 100% while specificity ranged between 65%-83%. This 
clearly denotes high diagnostic values of these tests in such 
cases. However, in cases of possible- IPA, the sensitivity, 
specificity, PPV, and NPV of PCR were 69.7%, 65.2%, 32.4%, 
and 90%, respectively. These values for ELISA, in possible-
IPA, were were 24.2%, 66.7%, 14.8%, and 78.6%, respectively. 
This strongly suggest that PCR has greater diagnostic role in 
possible-IPA as compared to those of serological tests. The 
diagnostic role of PCR was also higher than serological tests 
in cases with non-IPA. However, ELISA do play a diagnostic 
role in non-IPA, to an extent, as opposed to DID and DBA.
4. Discussion
  The frequency of secondary bacterial lung infection is high 
in lung malignancies due to the immunosuppressive state. 
The studies looking for the bacterial profile in BAL-fluids 
from patients of bronchogenic carcinoma, and especially 
the extended-spectrum 毬-lactamases (ESBLs) producing 
isolates, are fragmentary. 
  The first CTX-M class of extended spectrum 毬-lactamase 
(ESBL) was described in Germany[17], and since then more 
than 90 variants have been reported (http://www.lahey.org/
studies/inc_webt.asp). In India, the very first report of the 
presence of CTX-M-producing Enterobacteriaceae came 
from New Delhi on six isolates[18]. Since then several Indian 
surveys have reported the presence of ESBLs in clinical 
isolates based on phenotypic tests. We were unable to 
find any Indian report in our search of the literature using 
the Entrez PubMed database provided by the National 
Centre for Biotechnology Information (www.ncbi.nlm.nih.
gov/entrez) that specifically looked for blaCTX-M and then 
determined the precise genotype present, except one of our 
recently published report[7]. Moreover, we could not get any 
report, globally, looking for the secondary bacterial infection 
harboring bla genes in bronchogenic carcinoma patients. 
  It is interesting to note that CTX-M-15 is the only existing 
type, reported to date, in India however, diversity of CTX-M 
types within a single country have been reported [19, 20]. 
Therefore, we found worth looking occurrence of CTX-M 
genogroups, specific CTX-M types, and their genetic 
environment in CTX-M carrying- E. coli and K. pneumoniae 
isolates obtained from bronchogenic carcinoma patients; and 
to compare any relatedness or diversity with those of isolates 
obtained from other clinical sources. In this study, 48 of 62 
(77.4%) isolates produced CTX-M-15 and no other CTX-M-
type ESBL was found.  This finding was surprising: other 
surveys have reported a diversity of CTX-M types within a 
single institution or country[19-21]. We found a high level of 
co-resistance in isolates producing CTX-M-15 ESBL, which 
has been reported for many CTX-M producing isolates[22, 23]. 
In our survey, a total of 64.5% isolates were resistant to 
gentamicin, 85.5% to trimethoprim and 79% to ciprofloxacin. 
Resistance to cefoxitin was noted in 38.1% E. coli and 51.2% 
K. pneumoniae and was thought to be due to the presence of 
plasmidic blaampC. This transferable resistance determinant 
is clinically significant as it confers resistance in the host to 
beta-lactam-beta-lactamase inhibitor combinations as well 
as to narrow spectrum penicillins and expanded spectrum 
cephalosporins but spares fourth-generation cephalosporins 
such as cefepime and cefpirome. A total of 14.3% (3/21) 
isolates of E. coli were resistant to meropenem, whereas all 
K. pneumoniae isolates were susceptible to meropenem. 
  The association of insertion sequences with antibiotic 
resistance genes has been reported previously[24, 25]. ISEcp1 
is always found upstream of blaCTX-M-15 and is strongly 
implicated in the mobilization of this antibiotic resistance 
gene[26]. IS26 has also been reported in association with 
blaCTX-M including blaCTX-M-15 and more specifically, has 
been found to insert within ISEcp1, although interestingly, 
the insertion of IS26 differs from strain to strain[27]. In our 
study of highly diverse E. coli and K. pneumoniae producing 
CTX-M-15, IS26 was detected in 41.7% isolates, indicating 
high frequency of association of this element with blaCTX-M-
15. It was interesting to note that PCR products of variable 
sizes were detected, and an amplicon of 850 bp was 
most frequently observed. Such diversity of varying IS26 
amplicons was also noticed in other collections of bacterial 
isolates from different clinical samples. Numerous reports 
from India have indicated a high prevalence of ESBLs in 
Gram-negative bacteria, which must be presumed to have 
taken a considerable time to reach a high prevalence. Our 
present consecutive study also suggests that CTX-M-15 is 
the most common, or maybe the only, CTX-M type in India. 
  Acquisition of ampC-type genes by plasmids in K. 
pneumoniae and E. coli has been known since 1989, but 
only recently they are being reported with increasing 
frequency[28]. Despite of increasing recognition of this 
resistance mechanism worldwide, there is paucity of data 
from India, and most studies only present phenotypic 
data[29]. In our search of the scientific literature from the 
Indian subcontinent, we found only two publications that 
have characterized blaampC at the molecular level, and these 
report the presence of blaBIL-1-like and blaCMY-4[30, 31]. We 
report here the presence of blaampC of the CIT family in 
Indian Enterobacteriaceae in significant numbers (27.4%). 
Sequencing of representative isolates showed the presence 
of blaCMY-6, which is in addition those previously published 
reports.
Mohammed Shahid et al./Asian Pacific Journal of Tropical Medicine (2010)5-12 11
  We noticed slightly higher frequency of occurrence of 
blaampC in K. pneumoniae (29.3%, 12/41) as opposed to E. 
coli in (23.8%, 5/21) and this finding is in contrast to earlier 
reports[32]. We presume that plasmid host range and success 
amounts for these differences. 
  Simultaneous occurrence of non-CTX-M ESBLs and AmpC 
毬-lactamases has been reported in the literature[33, 34]. 
However the data is still fragmentary on the simultaneous 
occurrence of AmpC and CTX-M enzymes, and recently 
reports start coming on such combination resistance 
mechanisms[35, 36]. Analyzing our blaampC carrying isolates for 
co-carriage of blaCTX-M, we noticed simultaneous occurrence 
in 21% isolates. Spreading of ESBL-producing strains with 
ampC genes is a concern and poses a serious therapeutic 
problem, as carbapenems remain the only active 毬-lactam 
against these organisms[37]. This information is crucial 
for controlling the spread of resistance and for decision 
of empirical selection of antimicrobial agents. RAPD-
typing of the isolates demonstrated great diversity and no 
predominant type, indicating either horizontal transfer and/
or mobilization of these genes on plasmids. 
  To the best of our knowledge, this is the first report 
characterizing the occurrence and prevalence of CTX-M- 
and AmpC-producing enterobacteria from patients of 
bronchogenic carcinoma. We report here a 3GC resistance 
rate of 96.8% of all E. coli and K. pneumoniae obtained 
from BAL of BCA patients and in these, a CTX-M carriage 
rate of 77.4%. blaampC of CIT-family were detected 
in 27.4% of isolates. Our report supports the urgent 
need for regular screening and national surveillance 
characterizing the CTX-M types and to implement strict 
antibiotics policy to limit the irrational use of antibiotics, 
including cephalosporins, so as to minimize antibiotic 
selective pressure. We also emphasize that all patients 
of bronchogenic carcinoma should also be screened for 
secondary bacterial infections, along with secondary fungal 
infections, with these resistant bugs so as to introduce 
specific antibacterial therapy and to prevent unwanted 
death of the bronchial carcinoma patients because of 
these secondary infections.  In consequence to our earlier 
report, present study also suggests strong association of 
aspergillosis with lung cancer and further strengthens the 
potential use of non-validated serological tests suggested 
earlier.
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